Loading search results
Sponsor study identifier
interventional
36
0 countries
N/A
Study Start
November 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
May 30, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 30, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Goals: to compare the effects of two distinct rehabilitation protocols (conventional shoulder musculoskeletal rehabilitation combined with aerobic exercises versus solely conventional shoulder musculoskeletal rehabilitation) on shoulder pain, function, strength, kinematics and tendon thickness in patients with type 2 DM after 12 weeks of intervention and a subsequent follow up of 8 weeks. The secondary objective of this study will be to evaluate the association between AGEs accumulation and shoulder pain, function, strength, kinematics and tendon thickness in individuals with type 2 DM. Methodology: is a single-blinded randomized controlled trial, in which all subjects with a clinical diagnosis of type 2 DM (with at least 1 year of diagnosis), of both sexes, between 40 and 70 years, presenting shoulder pain (uni or bilateral) for at least 3 months with a pain intensity score from 3 points on a numerical rating scale for pain intensity, will be invited to participate. The main outcomes of this study will include the AGEs accumulation through skin autofluorescence measurement; shoulder pain through NRS scales; shoulder function through SPADI questionnaire and range of motion measurement; isometric shoulder muscles strength through manual muscle dynamometer measurement; shoulder kinematics through three dimensional inertial units measurements; supraspinatus tendon thickness through ultrasound measurement. All these outcomes will be measured before and after the rehabilitation protocols. Participants will be randomly assigned to one of the two rehabilitation groups: specific shoulder rehabilitation protocol group (SRG); or 2) specific protocol of shoulder rehabilitation plus aerobic exercise group (ARG). All individuals will be evaluated before starting the rehabilitation protocol (baseline) and at the end of rehabilitation (post 12 weeks) and 8 weeks after the end of the rehabilitation (follow up). For the statistical analysis, to verify the effectiveness of protocols over time, a variance analysis (ANOVA) of mixed model with Bonferroni adjustment will be performed for pairwise comparisons. Variables that do not meet the ANOVA assumptions will be analyzed by the Mann-Whitney and Wilcoxon tests with Bonferroni correction a priori. In order to assess the secondary objective of the study, correlation tests depending on data distribution will be performed (Pearson or Spearman correlation tests). A simple linear regression analysis will also be performed in order to analyze how much the AGEs accumulation can explain the alterations in the musculoskeletal and biomechanical variables. The significance level will be set at 5%.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 30, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 16, 2021
Actual (reported)March 26, 2021
Actual (reported)November 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 30, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 30, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
HbA1c - Glycated hemoglobin
HbA1c (mmol/mol) will be evaluated through blood tests that will be performed in the clinical laboratory of the University, at the beginning (before starting the treatment protocol), after the 12-week intervention (3-7 days after the last session) and after the 8-week follow-up.
12-weeks
lipid profile
lipid profile (mmol/L) will be evaluated through blood tests that will be performed in the clinical laboratory of the University, at the beginning (before starting the treatment protocol), after the 12-week intervention (3-7 days after the last session) and after the 8-week follow-up.
12-weeks
fasting glucose
fasting glucose (mmol/L) will be evaluated through blood tests that will be performed in the clinical laboratory of the University, at the beginning (before starting the treatment protocol), after the 12-week intervention (3-7 days after the last session) and after the 8-week follow-up.
12-weeks
SRG group: the group will only perform mobility and strengthening exercises involving the shoulder complex. ARG group: The ARG group will perform the shoulder rehabilitation protocol presented above combined with the aerobic exercise program that will last 20 minutes per session at 40% of the reserve heart rate (HRC), progressing up to 40 minutes with a maximum of 60% of the HRC in the last two weeks, according to the recommendations for patients with type 2 DM proposed in the American College of Sports Medicine Guidelines.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Habechian FAP, Flores Quezada ME, Cools AM, Kjaer BH, Cuevas Cid RI, Zanca GG. Shoulder-specific rehabilitation combined with aerobic exercises versus solely shoulder-specific rehabilitation in patients with type 2 diabetes mellitus: study protocol for a randomized controlled superiority trial. Trials. 2022 Aug 17;23(1):678. doi: 10.1186/s13063-022-06647-5.
First Submitted
March 16, 2021
First Posted
March 26, 2021
Study Start
November 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
AGEs accumulation measurement
Skin autofluorescence (nm wavelength) is considered as a substitute variable of AGEs accumulation. To perform this measurement, the AGE Reader (DiagnOptics, Groningen, the Netherlands) will be used, which non-invasively assesses skin autofluorescence.
12-weeks
Shoulder pain measurement
Shoulder pain will be evaluated through the numerical pain scale (Numerical Rating Scale 0 to 10, the higher the score, higher the pain).
12-weeks
Shoulder function measurement SPADI
The participant must respond to the SPADI questionnaire (Shoulder Pain and Disability Index - Spanish validated version).The SPADI score can range from 0 % indicating no pain or disability, to 100 % indicating severe pain and total disability
12-weeks
Shoulder function measurement Range of motion
the range of motion will be measured (in degrees) for all shoulder complex movements using a digital inclinometer (Acumar™, Lafayette Intrument Company, Lafayette, IN).
12-weeks
Isometric shoulder muscles strength measurement
Isometric muscle strength of the shoulder muscles will be assessed (in Newton) using a hand held dynamometer (HHD) (Lafayette Instrument, Lafayette, IN).
12-weeks
Shoulder three dimensional kinematics
Shoulder three-dimensional kinematics (in degrees) will be recorded (80 Hz) during arm elevation in the scapular plane and during a reaching over 90° functional task, using an inertial movement units system (IMU system) (MTW Awinda Xsens, Nexgen Ergonomics, Canada).
12-weeks
Supraspinatus tendon thickness measurement
Ultrasonographic measurement for each participant's supraspinatus tendon thickness (millimeters) will be scanned by using a Lumify Ultrasound in conjunction with a 4-12 MHz linear transducer (Philips Medical System).
12-weeks
Primary Completion
May 30, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 30, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
March 26, 2021
Record last verified: 2021-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: